T3399
凝血酶 来源于牛血浆
lyophilized powder, 50-150 NIH units/mg protein (biuret)
别名:
IIa 因子
form
lyophilized powder
specific activity
50-150 NIH units/mg protein (biuret)
composition
Protein, ~50%
UniProt accession no.
storage temp.
−20°C
Gene Information
cow ... F2(280685)
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
丝氨酸蛋白酶，选择性断开纤维蛋白原中的精氨酸-甘氨酸键，形成纤维蛋白以及纤维蛋白肽 A 和 B。
Physical form
Lyophilized powder containing sodium chloride and Tris-HCl
Preparation Note
Prepared using rabbit brain thromboplastin for conversion to the active form.
Analysis Note
基于 Biggs 改性法的 NIH 分析过程使用 0.2mL 稀释血浆（由血浆与等量生理盐水混合制得）作为底物，以及 0.1mL 凝血酶样品（在含 1% 白蛋白缓冲液中保持稳定）。只使用 15-25 秒之间的凝血时间分析凝血酶浓度。
活性是通过与一种K批次的NIH凝血酶参考标准品进行直接比较而得到并以NIH单位进行表达的。
Other Notes
查看更多关于 凝血酶的信息， 请访问 www.sigma-aldrich.com/enzymeexplorer。
signalword
Danger
hcodes
Hazard Classifications
Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay.
Pancras C Wong et al.
Hospital practice (1995), 41(1), 19-25 (2013-03-08)
The effect of the oral direct activated factor X (factor Xa) inhibitor apixaban on tissue factor-induced thrombin generation in human plasma was investigated in vitro using the calibrated automated thrombogram (CAT) method and compared with the oral direct factor Xa
Dabigatran: a nephrological way out.
Patricio A Pazmiño
The American journal of medicine, 126(4), e21-e21 (2013-03-20)
Ildiko M Kovach et al.
Biochemistry, 52(14), 2472-2481 (2013-03-23)
Thrombin is the pivotal serine protease enzyme in the blood cascade system and thus a target of drug design for control of its activity. The most efficient nonphysiologic inhibitor of thrombin is hirudin, a naturally occurring small protein. Hirudin and
Response.
Sarah T Garber et al.
Journal of neurosurgery, 118(2), 483-483 (2013-03-16)
Christopher S King et al.
Chest, 143(4), 1106-1116 (2013-04-03)
Thromboembolic diseases are common. Heparins and the vitamin K antagonists have been the mainstay of therapy for > 60 years, but both classes of agents have limitations. The "ideal" anticoagulant should be as effective and safe as heparin and vitamin
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持